Baird analyst Madhu Kumar downgraded Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) from Outperform to Neutral with a price target of $27.00.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE